Head to head

DSIP vs Ipamorelin

NootropicGH secretagogue

Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.

Verdict

Not an either/or

DSIP and Ipamorelin appear in each other's stacks in this dataset, so the most common real-world use is together rather than instead of. If you do have to pick one, let route and schedule decide it — DSIP is subcutaneous, intramuscular, once daily; Ipamorelin is subcutaneous, once daily — because the evidence does not separate them cleanly enough to do it for you.

What you are actually choosing between

Before anything else: the dataset lists DSIP and Ipamorelin in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

These sit in different classes. DSIP is a nootropic; Ipamorelin is a growth hormone secretagogue. They get compared because of where they overlap, not because they are interchangeable.

The overlap is recovery and sleep. On this site's goal weighting — an editorial priority score, not a measure of effect size — DSIP rates 4/5 for recovery and sleep and Ipamorelin rates 4/5. Outside that overlap only Ipamorelin goes further, carrying weight for injury repair and muscle growth; DSIP's declared goals stop at the overlap.

The evidence

Neither has an evidence edge — both sit at the same tier. DSIP: some human data, but it is small, old, or uncontrolled; the controlled work is a handful of small studies from decades ago. Ipamorelin: some human data, but it is small, old, or uncontrolled; small early-phase work only; development was discontinued. Anyone telling you one is clearly better supported than the other is going beyond what is published.

How they differ in practice

DSIP is a subcutaneous injection and an intramuscular injection; Ipamorelin is a subcutaneous injection. Both are injected, so route does not decide this one.

Ipamorelin has a characterized half-life of 2 h; DSIP does not have one published here at all. That asymmetry is worth more than it looks — it usually tracks how much formal pharmacology has been done on a compound.

Committed time differs: DSIP runs 4 weeks, Ipamorelin runs 12 weeks.

Risk and difficulty

The contraindication lists are not the same: Ipamorelin flags active malignancy, which DSIP does not. If any of those describe you they remove a compound from consideration outright, regardless of everything above.

Ipamorelin is rated beginner here and DSIP intermediate. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

DSIP (Delta Sleep-Inducing Peptide)

DSIP is a nine-amino-acid peptide isolated in the 1970s by Monnier, Schoenenberger and colleagues from the cerebral venous blood of rabbits in electrically induced delta-wave sleep, which is where the name comes from. It is not approved anywhere and has no modern development program. The human evidence is old, small and sparse, and it does not show what the name implies. The controlled work is a handful of studies from roughly 1977 to the early 1990s, mostly with a few dozen subjects at most, and the effects on sleep architecture were modest and inconsistent between groups. Some of the more repeatable findings were not in insomnia at all but in chronic pain and in opiate and alcohol withdrawal. DSIP is not a sedative and does not behave like one: it does not reliably knock anyone out, and whether an injected dose crosses the blood-brain barrier intact in meaningful quantity is still disputed. Treat any claim of a strong hypnotic effect as unsupported. On dosing, the classic human studies gave roughly 25 nmol/kg intravenously - about 1.5 mg for a 70 kg adult - which is both a different route and a much larger amount than anyone injects subcutaneously today. That figure has deliberately NOT been used to set the ceiling here. The 100-500 mcg subcutaneous range with a typical dose around 200 mcg reflects contemporary community practice, taken shortly before bed; there is no trial behind that range, and no dose-response curve exists for this route. Plasma half-life is reported in minutes, so no hourly figure is listed. The four-week cycle length is convention rather than evidence - no study has run long enough to establish a course length, and nothing is known about tolerance or long-term use.

Ipamorelin

Selective ghrelin receptor (GHS-R1a) agonist that triggers a growth hormone pulse with little effect on cortisol or prolactin, which is the main reason it is chosen over hexarelin or GHRP-6. Published human work is limited to small early-phase and post-operative ileus studies; development was discontinued and it is NOT an approved medicine anywhere. Everything sold to consumers is research-chemical grade, so the community 100-300 mcg per dose range comes from practice rather than from a label.

Side by side

The numbers

DSIP compared with Ipamorelin
Attribute	DSIP	Ipamorelin
Class	Nootropic	GH secretagogue
Routes	Subcutaneous, Intramuscular	Subcutaneous
Dose range	100 mcg–500 mcg (typical 200 mcg)	100 mcg–300 mcg (typical 200 mcg)
Frequency	Once daily	Once daily
Half-life	Not characterized	2 h
Cycle length	4 weeks	12 weeks
Experience	Intermediate	Beginner
Evidence	Limited human data	Limited human data
Contraindications	Pregnant / nursing Under 18	Pregnant / nursing Active malignancy Under 18
Side effects	Injection site stinging or redness Morning grogginess or a hungover, heavy feeling on waking Vivid or unusually intense dreams Headache Dizziness or a brief drop in blood pressure shortly after injecting Paradoxical alerting - a minority of users report harder, not easier, sleep onset Transient flu-like malaise in the first few doses	Injection site redness or itching Head rush or flushing shortly after injection Water retention and morning puffiness Tingling or numbness in the hands, which can reflect carpal tunnel pressure Vivid dreams or grogginess when dosed pre-bed

Turn a typical dose into a mark on the syringe: DSIPIpamorelin

Goals

Where they overlap, and where they do not

Goal	DSIP	Ipamorelin
recovery and sleep	DSIP: 4/5	Ipamorelin: 4/5
injury repairone only	DSIP: —	Ipamorelin: 3/5
muscle growthone only	DSIP: —	Ipamorelin: 3/5
fat lossone only	DSIP: —	Ipamorelin: 2/5
longevityone only	DSIP: —	Ipamorelin: 2/5

They overlap on 1 goal and diverge on 4. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

MonographDSIP (Delta Sleep-Inducing Peptide)Mechanism, protocol, storage, sources.MonographIpamorelinMechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.